IP Management
IP & Licensing
We offer Charité and BIH employees advice and support on all aspects of intellectual property (property rights, know-how, material, data, software) and its commercialization. In addition, we provide information about funding for spin-off projects and accompany all startups at Charité during the founding phase.
We help external institutions and companies to find and license suitable technology offers.
For an efficient technology transfer, we cooperate with the external service provider Ascenion to evaluate and market the intellectual property of Charité and BIH.
If you have any questions, please do not hesitate to contact us. We will be happy to advise you!
Services for employees at Charité and BIH
- First point of contact for advice, valuation and exploitation of IP (intellectual property such as inventions, know-how, data, material, software, design, trademarks, copyright)
- Protection of IP (e.g. by patenting inventions)
- Licensing of IP - negotiation and granting of rights of use
- Review and negotiation of IP terms in research contracts
- IP check and provision of text modules or letters of recommendation for third-party funding applications
- Scouting - searching for innovative ideas, e.g. via our Ideensprechstunde
- Support in the spin-off of startups at Charité and BIH incl. participation of our partner Ascenion on behalf of Charité. Our actions are based on Charité's commercialization regulations and transparent spin-off terms (Key points for standard conditions with spin-offs, German only). Here you can also find our Spin-off Guide (German only).
- Advice on public funding opportunities for spin-offs from science
- Review, negotiation and signing of Material Transfer Agreements (MTAs)
- Forms and templates: invention disclosures and software disclosures (Please save the respective document on your computer in order to complete it. Then send the completed document by e-mail to ip-technologietransfer@charite.de)
- VITA training course „Increasing Impact: Publizieren und patentieren?" for employees of Charité and BIH
Services for external parties
Technology Offers
Technology Offers
-
Diagnostics
- TO_CH137_HSV signature antibodies predict the development of anti-NMDA receptor encephalitis
- TO_CH820_CD8 T-cell subsets as biomarkers for predicting non-fusion after spinal bone fusion surgery
- TO_CH879_Novel Iron-(III)-tCDTA-based contrast agents for MRI and methods for producing them
- TO_CH916_Prediction_of_neural_invasion_in_patients_suffering_from_pancreatic_cancer_using_PIGF_and_sFIt-1
- TO_CH949_The CXCR3alt-CXCL 11 chemokine system for diagnostic and therapeutic use in solid cancer
- TO_TM1191_Community_acquired Pneumonia-disease-course_prediction_with_a_5-gene_score
-
Therapeutics
- TO_CH023_Disease-improving drug in a lethal pediatric mitochondrial disease
- TO_CH027/2021_Pentagalloyl-Glucose for improvement of impaired biomechanics in pulmonary arteries and prevention of pulmonary hypertension
- TO_CH069_TCR/CD3-specific CAR NK-92 cells for purification of TCR-modified T cell products
- TO_CH935_CFTR modulators for treating ARDS & associated lung edema & other endothelial/epithelial barrier dysfunction
- TO_CH519_Cytokine-Loaded Microparticles in Hyaluronic Acid for Treatment of Osteoarthritis
- TO_CH833_Iloprost-release system for preventing delayed healing in patients with a musculoskeletal injury
- TO_CH845_Recombinant uromodulin to prevent vascular calcification in chronic kidney disease
- TO_CH886_T-cell therapy of MYD88L265P-dependent B-cell lymphoma
- TO_CH895/2018_Complement Anaphylatoxin Binding Peptide for treating Ocular Fibrosis
- TO_CH969_Reprogramming immune cells to develop allogenic CAR cell-based therapies
- TO_CH970_CH928 Next generation allogeneic CAR-NK cell platform for treatment of malignant diseases
- TO_CH980_CRISPR-Cas induced immunosuppressant resistance in anti-viral T cell products for clinical application
- TO_CH984_Particle-mediated transport of dissolved active agents into hair follicles enhance delivery to and penetration in the skin
- TO_Human TCR constructs for adoptive cell therapy of cancer (CH974 - Rac1/2 ; CH97 – TGFb ; CH945 – HPV ; CH889 – CD22)
-
MedTech
- TO_CH005_High-level recombinant adeno-associated virus production
- TO_CH021_Fiber Membrane Oxygenator with Minimized Priming Volume
- TO_CH422_Blood transfusion safety system Cairos
- TO_CH722/2014_Novel Stapler for cutting and clamping solid organs
- TO_CH783_Method and arrangement for identification and correction of optical aberrations
- TO_CH915_A scalable and highly sensitive assay for measuring extracellular NAD+ level in human body fluids
- TO_CH951_High Performance Paclitaxel-Coated Balloon Catheters
- TO_CH967_Non-invasive pressure gradient prediction for a cardiovascular narrowing
Technology Offers on the website of Ascenion
You can also find an overview of our technology offerings at our technology transfer service provider Ascenion GmbH. Please filter on this page under 'Institute of Origin' for Charité - Universitätsmedizin Berlin.
If you are interested, please contact us.
Patent or publication? Best hand in hand!
Many scientists think that publishing and patenting are mutually exclusive. However, patenting IP (intellectual property) is the best way to make the findings available to as many patients as possible.
Without patenting a technology, it will not reach patients in mainstream care. This is because external companies as licensees would otherwise have no incentive to make appropriate investments to develop the technology to market maturity.
If you are currently involved in a publication, remember to contact us early on for protection of your intellectual eIgent. Please feel free to book a free and confidential consultation at our Idea Office - together we can generate more impact out of your idea.
Other important information
- Inventions must be reported to the employer. Please use the invention disclosure form (please download to open).
- In this context, Charité BIH Innovation assumes the rights and obligations of the employer.
- According to § 4 ArbErfG, a service invention is an invention that is related to the service-related work content of the university employee.
- The university must decide within 4 months whether to claim the reported invention.
- The university decides in which countries a patent application should be filed. Countries in which the university does not want to file an application will be released to the inventor / inventor community.
How does the Charité-inventor benefit of disclosing an invention?
Since 2002, the Employee Inventions Act (ArbErfG) has created a new legal framework that significantly improves and simplifies the filing and exploitation of patents for universities and is linked to an attractive profit-sharing scheme for all university employees:
- Service inventions by university employees are the property of the university, which bears the costs and the economic risks.
- The inventor or the inventor community receives 30% of the gross proceeds. This means that the inventors are compensated even if, for example, the patent costs exceed the patent proceeds.
- The university inventor is exempt from bureaucratic formalities, does not have to bear any costs and is only required to provide support in the course of the patent application. The patent administration is taken over by the IP & Licensing Team of the Charité.
- The patent applications published 18 months after filing also constitute publications.
| 190 | translational projects |
| 502 | patents |
| 141 | patent families |
| 27 | supported startups |
| 40 | annual invention disclosures |
| 7 Mio. € | annual revenues |
![[Translate to englisch:]](/fileadmin/_processed_/1/3/csm_Claudia_Keil-Dieckmann_Portrait_87095b89e8.webp "[Translate to englisch:]")
